CareDx Posts Strong Q2 2026 Growth on Testing Services Surge
Event summary
- CareDx reported $132M in Q2 2026 revenue, up 52% YoY, driven by a 61% increase in Testing Services revenue to $100M.
- The company closed the sale of its Lab Products business to Eurobio Scientific on June 30, recognizing a $113M gain on sale.
- CareDx completed the acquisition of Naveris, strengthening its position in precision medicine diagnostics for transplant, specialty oncology, and cell therapy.
- GAAP net income swung to $111M from a $9M loss in Q2 2025, with adjusted EBITDA rising to $25M from $5M.
The big picture
CareDx's Q2 2026 results reflect a strategic pivot towards precision molecular diagnostics, with the divestiture of its Lab Products business and acquisition of Naveris positioning it for focused growth in transplant and specialty oncology. The company's strong revenue and profitability gains underscore the increasing demand for molecular surveillance testing in transplant care, supported by favorable reimbursement dynamics.
What we're watching
- Integration Challenges
- How CareDx will integrate Naveris and sustain momentum in its core transplant diagnostics business.
- Reimbursement Dynamics
- Whether CMS's finalized Medicare coverage policy for AlloSure® and AlloMap® will support continued patient access and revenue growth.
- Pipeline Progress
- The pace at which CareDx advances its AlloHeme® pipeline program and HistoMap® Kidney data toward commercialization.
Related topics